After the final STZ administration, the blood glucose levels of the STZ-treated DGKα+/+ and DGKα−/− mice increased at 1 week, confirming the induction of diabetes (DGKα+/+ STZ: 384 ± 109.19 mg/dL, DGKα+/+ STZ + VtE: 385.27 ± 45.78 mg/dL, DGKα−/− STZ: 339.68 ± 89.63 mg/dL, DGKα−/− STZ + VtE: 339 ± 77.8 mg/dL). The gene discussed is DGKA; the disease is diabetes mellitus.